PDF(Pubmed)
Abstract：
Human leukocyte immunoglobulin (Ig)-like receptors (LILR) are a family of 11 innate immunomodulatory receptors, primarily expressed on lymphoid and myeloid cells. LILRs are either activating (LILRA) or inhibitory (LILRB) depending on their associated signalling domains (D). With the exception of the soluble LILRA3, LILRAs mediate immune activation, while LILRB1-5 primarily inhibit immune responses and mediate tolerance. Abnormal expression and function of LILRs is associated with a range of pathologies, including immune insufficiency (infection and malignancy) and overt immune responses (autoimmunity and alloresponses), suggesting LILRs may be excellent candidates for targeted immunotherapies. This review will discuss the biology and clinical relevance of this extensive family of immune receptors and will summarise the recent developments in targeting LILRs in disease settings, such as cancer, with an update on the clinical trials investigating the therapeutic targeting of these receptors.
摘要：
人类白细胞免疫球蛋白（Ig）样受体（LILR）是11个先天免疫调节受体的家族，主要在淋巴和骨髓细胞上表达。LILR是激活的(LILRA)或抑制的(LILRB),这取决于它们相关的信号传导结构域(D)。除可溶性LILRA3外，LILRAs介导免疫激活，而LILRB1-5主要抑制免疫反应并介导耐受性。LILRs的异常表达和功能与一系列病理有关，包括免疫功能不全（感染和恶性肿瘤）和明显的免疫反应（自身免疫和同种反应），提示LILRs可能是靶向免疫疗法的优秀候选者。这篇综述将讨论这个广泛的免疫受体家族的生物学和临床相关性，并将总结在疾病环境中靶向LILR的最新进展。比如癌症，随着研究这些受体的治疗靶向的临床试验的更新。
